Wealth Enhancement Trust Services’s Denali Therapeutics DNLI Stock Holding History

Wealth Enhancement Trust Services’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67K	Buy	+65	New	+$1.34K	﹤0.01%	1029

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wealth Enhancement Trust Services's DNLI Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 65 shares worth $1.67K. The stake represents ﹤0.01% of the portfolio and ranks #1029 among its holdings.

191 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Wealth Enhancement Trust Services held 65 shares of Denali Therapeutics worth $1.67K as of Q2 2026.
Denali Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1029 holding.
191 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.